extensive view on the current state of systemic metabolism. Metabolomics has become increasingly popular in canine 37 studies. It is especially suitable in characterizing metabolic effects of multiple environmental and inter-and intra-38 individual 1 factors including feeding 2-6 , aging 7 , inter-breed differences 8,9 , drug action 10,11 , behavior 12,13 , exercise 14 , 39 genetic factors 15 and pathological processes 16-26 . 40 Mass spectrometry (MS) and proton nuclear magnetic resonance (NMR) spectroscopy are the two main technologies for 41 metabolic profiling, both in human and animal studies 27 . Proton NMR spectroscopy offers quantitative data with high 42 reproducibility, high throughput and excellent scalability in a non-destructive and cost-effective manner 27 . NMR 43 spectroscopy is well suited for the scientific use of large cohorts and biobanks 28, 29 and is highly suitable for studies 44 combining different omics technologies [29] [30] [31] . Due to the quantitative and highly reproducible nature of NMR 45 spectroscopy, it can be easily utilized as a diagnostic tool and research findings can be easily applied to clinical use. 46
Metabolomics holds great potential in clinical diagnostics. It is a promising tool for highlighting the metabolic 47 alterations associated with the emergence and progression of diseases, early disease detection and individualization of 48 treatment [32] [33] [34] . Clinical diagnostics and decision-making have formerly relied on the use of single clinical chemistry 49 biomarkers. The routinely used approach is largely unusable for risk prediction, since changes are typically only seen 50 when the diseased state has already been reached 33, 35 . Thus, preventive and supportive care measures cannot be 51 undertaken before organ failure is already present. Interpretation of the results by the traditional approach might also be 52 challenging, since multiple simultaneous metabolic phenomena can affect the interpretation of these results and multiple 53 diseases can be associated with similar laboratory results 22,35-37 . Moreover, evaluations of disease severity lack accuracy 54 when only one affected metabolic pathway is taken into account 34, 37 . Furthermore, traditional diagnostic approaches do 55 not take the metabolic state of the patient into account, although it might have an impact on the best treatment of the 56 patient 34, 38 . 57
The prerequisites for the utility of a particular method include documentation of the method's reproducibility, 58
understanding of confounding factors that might affect the interpretation of the results, and the formation of reference 59 intervals 39 . All of these factors have previously been largely unpublished in the canine metabolomics field. In this study, 60 we describe the development and validation of a novel NMR-based metabolomics platform for dogs, demonstrate its 61 performance characteristics, publish the determined dog-specific reference intervals for its biomarkers and demonstrate 62 its utility in a practical situation. 63 64 To develop and validate a quantitative NMR-based approach for canine metabolomics, a total of 8247 serum or plasma 66 samples were collected and analyzed. Thirty of these were pooled samples, 912 were replicate samples of client-owned 67 dogs, 999 leftover clinical laboratory samples, and 6306 were single samples of client-owned dogs (Supplementary 68 Figure 1 ). The number of individual client-owned dogs with samples collected during this project was 6164 69
( Supplementary Table 1 ). Eighteen percent of the dogs were under one year of age, 61% aged 1-7, and 21% over 7 70 years of age. Males consisted 40% of the population and samples were taken from 256 breeds. 71 Glycine/BCAA 0.3-1.4 0.3-1.5 0.4-3.0 a 0.3-1.2 0.3-1.2 BCAA/Tyrosine 3.7-9.5 3.8-9.2 3.8-8.3 a 3.9-9.5 3.5-8.6
Phenylalanine/tyrosine 0.6-1.2 0.5-1.0 0.5-1.1 0.5-1.0 0.5-1.0
Glycine/valine 0.6-2.6 0.7-3.0 0.9-6.8 a 0.7-2.5 0.7-2.6
Alanine/BCAA 0.7-2.0 0.6-1.6 0.6-1.4 0.5-1.6 0.6-1.8 a Alanine/valine 1.3-3.7 1.2-3.5 1.3-3.0 1.1-3.5 1.3-3.8 VLDL lipids mmol/l 0.1-1.1 0. : no overlap between the 90% CI of the lower reference limit of this age group compared to adult dogs 112 113
Precision of the platform 114
We studied analysis precision using three biologically different dogs, with duplicate aliquots of each dog's sample 115 analyzed once a day during a twenty-day period ( Supplementary Table 3 ). The aliquots from a senior dog suffering 116 from hyperadrenocorticism showed marked chylomicronemia, and was excluded from method precision estimations. 117
Outlier removal slightly affected result interpretation, thus results were evaluated with outliers removed. In the 118 primarily evaluated (non-chylomicronemic) samples, 110/123 biomarkers reached all of their precision goals. Albumin 119 did not reach its primary precision goal of ASVCP CV min based on biological variation, but reached all its other 120 precision goals; CV% goal based on ASVCP Clinical Decision Limits and the S T goal of under 1/8 reference width 121 20% (CV maxBG ), but did not meet their secondary precision goal of S Tmax . 12/123 biomarkers did not reach their primary 123 precision goal of CV maxBG , but reached the S Tmax goal. All of these analytes were lipid analytes with high inter-124 individual biological variation and large reference interval width, and were in low concentrations in the tested samples. 125
The CV maxBG goal was thus regarded inappropriate for these analytes, since the variation in these analytes' 126 concentrations was not considered to affect clinical decision-making. 127
Chylomicronemia caused imprecision in multiple lipid measurements as well as in creatinine and the amino acids 128 leucine and phenylalanine. Precision of glutamine was non-evaluable, since the olefin oligomer gel in the sample tubes 129 inhibited correct glutamine estimation from the NMR signal. The precision of XL-VLDL phospholipids was non-130 evaluable due to a large amount of missing observations caused by physiologically very low analyte concentrations in 131 healthy dogs. 132
The effect of sample storage on biomarker stability 133
All evaluated analytes remained stable in refrigerated temperature for 7 days (Table 2 , Supplementary Table 4 ). Most of 134 the analytes remained also stable at room temperature for 7 days. Unstable metabolites in room temperature were the 135 amino acids histidine, isoleucine, glutamine, tyrosine and phenylalanine, acetate, triglycerides and certain lipoprotein 136 particle constituent concentrations as well as the fatty acid docosapentaenoic acid. The stability of all other amino acids 137 than glutamine was better in EDTA-plasma than in serum. Glutamine concentration changed significantly at 4 days of 138 storage at room temperature in EDTA-plasma samples and at 7 days of storage in serum samples. The acceptable 139 change limit (ACL) of glutamine and XL-VLDL phospholipids could not be calculated using the analysis mean 140 coefficient of variation (CVa), since these were not available from the precision study. The changes observed in 141 triglyceride concentrations at room temperature originate from the computational quantitation based on lipoprotein 142 particle distribution and the lipid quantity in the lipoprotein particle core and their outer surface. These are slightly 143 affected by sample storage at room temperature, thus affecting triglyceride quantitation. 144
All of the evaluated analytes were stable at -80°C for 12 months. Storage at -20°C affected certain lipoprotein particles 145 and their composition, certain fatty acids, citrate, acetate and GlycA. Citrate levels were significantly (p < 0.05) 146 changed already at one week of storage at -20°C. 147
Heparin plasma storage samples rarely made under the p-value of 0.05, even when the mean percentage deviation 148 (MPD) exceeded the ACL and statistically significant (p < 0.05) changes were noted in other sample types. 149 outlier removal. In heparin plasma, outliers could not be reliably identified due to the small sample size (n = 4). 151 Table 2 . Critical storage times for analytes sensitive to certain storage conditions in at least one sample type. 
The effect of delayed plasma separation on biomarker stability 168
We studied the effect of delayed plasma separation in 34 EDTA plasma samples, which had been stored as whole blood 169 in the refrigerator for 24 and 48 hours before separating plasma ( Supplementary Table 5, table 3 ). Outlier removal 170 slightly affected result interpretation, thus the results were evaluated after outlier removal. Prolonged contact with red 171 blood cells (RBC) affected the concentration of many of the analytes. Significant changes (p < 0.05, MPD>ACL) after 172 one day's contact to RBCs in refrigerator temperature were observed for glucose and lactate. After two days' contact 173
with RBCs, significant changes were observed for citrate, amino acids alanine, histidine, isoleucine, leucine, valine, 174 phenylalanine and tyrosine, cholesterol, triglycerides, and lipoprotein particles and their constituents. Glutamine values 175 were also changed significantly (p < 0.05) at 48 hours of storage as whole blood, but MPD could not be evaluated 176 against the ACL due to the missing ACL. 177 
Sample tube validation 186
We studied the differences of seven different sample tubes and the variability between their two sample lots using 187 samples from 20 client-owned dogs ( Supplementary Table 6 ). Outlier removal did not affect result interpretation, thus 188 results were evaluated without outlier removal. 189
Firstly, the different sample tubes were compared to the primary reference tube (Vacuette Lithium Heparin). Most 190 analytes showed comparable results in all tube types compared to the primary reference tube. Significant differences (p 191 < 0.05) with MPD > ACL were noted for citrate, glucose, lactate and GlycA and significant differences (p < 0.05) with 192 MPD < ACL were observed for glutamine, histidine, pyruvate and acetate. Glutamine showed significant differences (p 193 < 0.05) compared to the primary reference tube, but its ACL was not available. Most of this variability was observed 194 between analyte values in serum and plasma. 195
Secondly, analyte values in all serum tubes were compared to the reference serum tube (Vacuette Z Serum Clot 196 Activator). All serum tubes showed comparable results with the serum reference tube for all metabolites. 197
The only lot-to-lot variability was observed in MiniCollect Serum gel tubes for glutamine and GlycA. Results obtained 198 by both of these tube lots were still comparable to the reference serum tube (Vacuette Z Serum Clot Activator). In these 199 having undergone changes in physical appearance, while sample tube constituents had remained the same. 201
Interference studies 202
We studied the interference of hemolysis, lipemia, and unconjugated and conjugated bilirubin using triplicate samples 203 of two different test pools for hemolysis and bilirubinemia and from one pool for lipemia ( Supplementary Table 7) . 204
Hemolysis interfered with the quantitation of albumin and certain lipids; lipoprotein particle cholesterol concentrations, 205 total triglycerides and certain lipoprotein triglyceride measures, multiple fatty acids, LDL and VLDL particle size, 206 certain lipoprotein particle concentrations, lipoprotein phospholipids and certain lipoprotein lipids. Bilirubinemia 207 interfered only with the quantitation of L-VLDL esterified cholesterol and S-HDL triglycerides. Lipemia affected the 208 quantitation of GlycA due to the lipid contribution to the GlycA signal. However, the concentration of GlycA remained 209 above the reference interval after the removal of lipids, indicating that lipemia was not the sole cause for raised GlycA 210 concentration in the lipemic pool. 211
Method comparison 212
Using 999 clinical canine samples, we evaluated, whether results of routine clinical chemistry analytes in the NMR 213 metabolomics platform are comparable with results obtained by conventional clinical chemistry methods 214 (Supplementary Table 8 ). The tested metabolites were glucose, lactate, creatinine, albumin, cholesterol and 215 triglycerides. The tested samples covered the clinical concentration ranges for all analytes. The comparison plots 216 showed satisfactory agreement between the two methods for all analytes. In some metabolites, logarithm transformation 217 showed better agreement than initial data, suggesting better agreement in the transformed data. 218 219 Glucose, lactate and albumin measurements reached the Total Allowable Error (TE a ) goals based on ASVCP Clinical 220 Decision limits 41 , indicating that the two methods can be used interchangeably without affecting clinical decision-221 making. The bias percentage of creatinine, cholesterol and triglycerides was too high for the analytes to reach the TE a 222 goals based on Clinical Decision limits, meaning that the two methods cannot be used interchangeably. Values obtained 223 by the conventional method can be evaluated against values obtained by the NMR method using the slope and intercept 224 calculated by Deming regression. 225
Hyperglycemia associates with many metabolic changes 226
We evaluated the practical relevance of the NMR metabolomics platform by comparing the metabolic profile of a 227 markedly hyperglycemic group (n = 24) to a normoglycemic group of routine laboratory diagnostic samples (n = 781). 228
Several biomarkers with previously reported changes in canine and human diabetes mellitus were significantly changed (p < 0.05) in the hyperglycemic group, including the BCAAs isoleucine, leucine and valine, GlycA, acetate, fatty acids, 230 cholesterol, triglycerides, lipoprotein particle concentrations and composition, phenylalanine and lactate 231 ( Supplementary Table 9 ). 232 Excellent fit in logistic regression modeling (smallest AICs and AUC values > 0.9), indicating good predictive value for 233 hyperglycemia, was observed for BCAAs and their ratios. Twenty metabolites had good fit (AUC < 0.8). 31 biomarkers 234 had a high proportion of missing values, reducing the comparability with other metabolites due to different sample 235 populations. There were 14 metabolites with good fit among these metabolites. Many of these metabolites are lipids, 236 that have very low concentrations in healthy dogs, causing a high proportion of automatically rejected very low values 237 by platform quality control. 238 239 Discussion 240
Metabolomics is a rapidly growing field holding great potential for numerous clinical and scientific applications. 241
Amongst various approaches, NMR spectroscopy is currently the most promising metabolomics method for clinical use 242 due to its' quantitative nature, high-throughput, accuracy and speed, all of which are currently not achievable with MS 243 based metabolomics. In this study, we describe a novel, cost-effective NMR metabolomics testing platform for dogs. A 244 similar approach has previously been demonstrated and widely utilized in human metabolomics 40 . The testing platform 245 is capable of quantifying 123 biomarkers from a 100 µl sample of serum, heparin plasma, EDTA plasma or citrate 246 plasma. The throughput for one device is ~200 samples per 24 hours and around 70,000 samples per year. The 247 turnaround time is currently 5 days and can be markedly reduced. These characteristics make this comprehensive 248 metabolomics platform a new high-throughput method to facilitate veterinary research and clinical diagnostics with 249 significant implications on treatment, care and well-being of dogs. 250
Recent advances in metabolomics research are paving the way from diagnostics based on single biomarkers to a more 251 holistic approach. Especially the management of chronic metabolic diseases is thought to benefit from a methodology 252 capable of generating comprehensive information on the metabolic state of the individual, enabling a personalized 253 approach to management of the disease 34 . Metabolomics is also proving itself valuable in disease risk prediction 33,42-44 . 254 In contrast to genetics, metabolomics offers real-time information of the metabolic state of the animal, taking 255 environmental factors and treatment into account. This offers metabolomics the possibility to be utilized as both a 256 diagnostic tool as well as a follow-up tool. The advantage of the holistic nature of the NMR metabolomics platform was 257 demonstrated in the comparison of hyperglycemic samples to normoglycemic samples from a routine laboratory 258 diagnostic sample population. The NMR metabolomics platform was able to identify a plethora of biomarkers with 259 significant differences between the hyperglycemic group and the normoglycemic group, including BCAAs, GlycA, 260 acetate, fatty acids, cholesterol, triglycerides and lipoprotein particle concentrations and composition, phenylalanine and 261 lactate. Many of these changes have been associated with canine and human diabetes mellitus, and even diabetes risk 262 before disease onset 16, 25, 34, 42, 44 . This suggests the possibility of the NMR metabolomics platform to enhance preventative 263 and precision veterinary medicine by providing new therapeutic targets and prognostic diagnostic markers. 264
In addition to a set of well-known clinical chemistry analytes, the established metabolomics platform includes a wide 265 range of previously clinically unquantified biomarkers. One of the most interesting novel biomarkers is GlycA, a 266 composite systemic inflammatory biomarker comprised of signals of acute-phase proteins The analytical method should be considered when evaluating laboratory results against treatment guidelines and 284 reference intervals 39 . The method comparison study revealed a linear relationship between the conventional and NMR 285 method for all analytes, but all results cannot be evaluated interchangeably. Triglyceride measurements showed most 286 variability between the two methods, explained by differences in methodology, sample handling and biological 287 characteristics. Analysis with the conventional method was done immediately, whereas NMR aliquots were frozen and 288 one batch partly thawed during shipment. The methodology is also different, NMR measures triglycerides within 289 lipoprotein particles, whereas the conventional method is based on interaction with the triglyceride molecule. Lipemia 290 also affects the precision of triglyceride analyses, which causes more variability in high analyte concentrations. 291
Correct preanalytical measures are considered essential for the integrity of laboratory results 54,55 . An appropriate sample 292 drawing technique is crucial for avoiding hemolysis, fasting before sample drawing for avoiding lipemia and prompt 293 RBC separation for avoidance of prolonged RBC metabolism. Hemolysis, bilirubinemia, lipemia and prolonged contact 294 with RBC all affected the quantification of certain metabolites. The profound impact of chylomicronemia on method 295 precision was caused by matrix heterogeneity due to the chylomicron cream layer formation, which could be reduced by 296 sample mixing immediately before analysis. Glycolysis-related metabolites are especially sensitive to contact with 297 RBC, causing plasma samples to have different concentrations of these analytes than serum samples. Prolonged contact 298
to RBCs affected also amino acids, which might explain why amino acid stability was better in our storage study using 299 plasma and serum samples, than in previous studies using whole blood 56, 57 . 300
It is critical to use sample storage and shipping conditions that preserve the integrity of laboratory results. All tested 301 analytes were stable at refrigerator temperature for one week, making refrigerated temperature the optimal sample 302 short-term storage and shipping temperature. Sample storage at room temperature should be minimized. Most amino 303 were more stable in EDTA-plasma samples than in serum samples in room temperature, which has also been reported in 304 previous studies 57 . The gold standard for long-term storage of serum/plasma metabolomics samples is freezing the 305 samples immediately after serum/plasma separation and keeping them frozen at -80°C until analysis and avoiding 306 additional freeze-thaw cycles 58 . All of the tested analytes remained stable during one year of storage at -80°C. Two 307 weeks of storage in -20°C was suitable for most of the analytes. 308
Limitations of this study include, that the precision and interference studies did not include samples at clinical decision 309 levels for all metabolites. Since the NMR platform is so extensive, acquiring these samples would have been extremely 310 difficult. The sample numbers especially in heparin plasma, were a limitation of the storage study. Limitations of the 311 method comparison study include lack of a reference method generating results that could be viewed as true values of 312 the analyte. No clinical data was available for the hyperglycemia study, thus the study should be repeated with samples 313 in confirmed diabetic animals. The identified analytes should also be studied for multicollinearity. 314
Owing to the advantages of quantitative results, high throughput and reproducibility, the NMR-based metabolomic 315 platform developed and validated here holds great potential for numerous clinical and research applications in and GlycA are well-known, and the quantitative and linear relationship between the signal intensity and molecular 335 concentration is an inherent property of NMR. Thus, these biomarkers can be quantified using the established NMR 336 techniques. The identification of signals for triglycerides, cholesterol, and lipoprotein subclass particles and lipids was 337 verified by analyzing 200 of the previously collected EDTA-plasma samples with different lipid concentrations by high-338 performance liquid chromatography 59 . For these measures, the concentration range of the automated NMR spectral 339 analysis was also calibrated against these results. 340
Once the initial method calibration was completed, we collected a total of 4683 serum and 495 lithium heparin plasma 341 samples across Finland during fall 2017-fall 2018 for use in our canine NMR metabolomics project. Samples were 342 collected from dogs of all available breeds, with an emphasis of including dogs from genetically and morphologically 343 different breed groups. Samples were drawn by cephalic venipuncture from client-owned dogs. Serum samples were 344 collected into MiniCollect serum gel tubes and were allowed to clot for 30-45 minutes before centrifuging them at 3,000 345
x g for 10 minutes to separate the serum. Heparin plasma samples were collected into MiniCollect lithium heparin 346 plasma gel tubes and the samples were immediately centrifuged at 3,000 x g for 10 minutes to separate plasma. All 347 samples were then stored at -80°C before NMR analysis. All dog owners completed a history form, that included 348 signalment and details about the health status, diet, exercise, stress and reproductive state of the dog. 349
The fatty acid panel verification and calibration was done using 100 samples with different lipid concentrations, 350 collected for the canine NMR metabolomics project. Reference fatty acid concentrations were obtained using a 351 chromatographical method by a commercial laboratory (Vitas as, Norway). 352
Reference intervals 353
Determination of reference intervals (RI) of healthy dogs was performed according to the American College of 354 Veterinary Clinical Pathology (ASVCP) reference interval guidelines 39 . We used the population-based nonparametric 355 method for RI calculation, and calculated 90% confidence intervals (CI) for the reference limits. A minimum of 120 356 samples is required for the use of this method. Inclusion in RI calculation was based on fasting duration (minimum of 357 12 hours), appropriate sample handling, and the lack of owner-reported biological confounding factors, including 358 diseases, severe anxiety/stress and strenuous exercise before blood collection. Each metabolite was examined for outliers before RI calculation. We used Box Cox transformation to find a normal 367 transformation, and Horn's algorithm in the transformed data to identify the outliers. In Horn's algorithm, the criterion 368 for rejection of values is exceeding interquartile (IQ) fences set at Q1 -1.5*IQR and Q3 + 1.5*IQR (IQR = interquartile 369 range; IQR = IQ3 -IQ1 where IQ1 and IQ3 are the 25th and 75th percentiles, respectively. Once we identified the 370 outliers, the sample and animal data were thoroughly reviewed for confounding analytical and preanalytical factors 371 before reaching a conclusion about sample exclusion. In metabolites, in which normal distribution was not found, 372
Horn's algorithm offered multiple outliers, which all were reviewed before reaching a conclusion about exclusion. 373 CIs and RI. It is recommended that CI should not exceed 0.2 times the width of the RI, since it may indicate, that the 375 sample number is insufficient. 376
Differences between RI for different age groups were evaluated by comparing the 90% CI of reference limits of puppies 377 and senior dogs to the 90% CI of reference limits of adult dogs. Differences in the reference limits were concluded to be 378 present, when there was no overlap between the 90% CI of reference limits between the two groups. 379
Precision 380
Precision of the NMR method was tested using three biologically different dogs (puppy, healthy adult, senior dog 381 suffering from hyperadrenocorticism). Blood was drawn by cephalic venipuncture into Vacuette 8ml Z Serum Sep Clot 382 Activator tubes. Samples were allowed to clot for 30-45 minutes and centrifuged at 2,000 x g for 10 minutes to separate 383 serum. Every sample was divided into 40 aliquots of 100µl. All samples were stored at -80°C before NMR analysis. 384
Two duplicate aliquots of each sample were analyzed each day during a twenty-day time period. 385
The sample from the senior dog suffering from hyperadrenocorticism had marked chylomicronemia with a chylomicron 386 coat forming on the top of the stored serum aliquots. The results of this sample were used to determine the effect of 387 chylomicronemia on test precision. 388
Total within-laboratory precision estimates were expressed both as coefficient of variation (CV%) and standard 389 deviation (S T ). These within-laboratory precision estimates were evaluated against laboratory precision goals. We also 390 calculated within-run precision, expressed as within-run standard deviation (S r ). All precision estimates were calculated 391 using methods described in CLSI EP5-A3 60 . Outlier detection was based on comparison of the absolute difference of 392 the two duplicate aliquots analyzed in the same run to the mean absolute difference of all duplicates from the same 393 sample. A difference that exceeded the mean absolute difference fourfold was set as the rejection line. If an outlier was 394 detected, the duplicate was excluded from the calculations. 395
The currently most advisable hierarchy for performance specifications for human diagnostic laboratories is: 1. 396 biological outcomes, 2. biological variation and 3. state-of-the-art 61,62 . Biological outcome-based performance goals 397 cannot be used in veterinary medicine, since they have not yet been published for animals. Canine CV% goals based on 398 biological variation are available for only a few analytes and can be so strict, that they are unachievable by clinical 399 laboratories and do not affect interpretation of the results 41 . State-of-the-art goals can lack accuracy and might not fit all 400 analytes. Due to the lack of specific performance goals for all analytes, we evaluated the precision results against a set 401 of performance goals. 402
In this study, ASVCP goals based on biological variation were set as the primary goals for CV%, since they are the only 403 canine-specific precision goals available 41 . The total accuracy of veterinary laboratory results is typically evaluated 404 using Observed Total Error (TE obs ) and evaluating it against against preset Total Allowable Error (TE a ) limits. TE obs can 405 be calculated as TE obs = Bias% + 2CV%. Bias was not applicable for this study as a deviation from a true value 41 . This 406 led us to use ½ of ASVCP TE a limits based on Clinical Decision Limits as our secondary precision goals for CV%. If 407 ASVCP goals were not set, we used 20% as the goal for CV% (CV maxBG ), which is generally considered an acceptable 408 laboratory error in metabolomics 63,64 . Since individual CV% max goals were not available for most of the analytes and 409 the 20% CV% goal might not be descriptive enough for metabolites that have a very wide or narrow reference range 410 due to inter-individual biological variation, we additionally compared the S T to the S Tmax goal of 1/8 of the width of the 411 reference range. This goal was based on the finding, that analytical variation over one quarter of the reference range is 412 considered to affect the clinical interpretation of the results 65 . The S Tmax goals based on 1/8 of the reference range width 413 were very descriptive of the effects of imprecision on clinical interpretation of the results, but have the drawback, that 414 imprecision affects the width of the reference range, itself 66 . 415
Sample storage study 416
To define the effects of sample storage and shipping conditions on analyte results, we studied the effects of both long-417 and short-term sample storage. Short-term storage was studied in room temperature and refrigerated temperature, and 418 long-term storage at -20°C and -80°C. To define storage effects in different sample matrices, we used three different 419 sample matrices: serum, EDTA-plasma and heparin plasma. The protocol of the sample storage study is presented in 420 Table 4 . 421
To study storage effects in these above-mentioned sample matrices, we took serum and EDTA plasma samples of seven 422 client-owned dogs in a separate sampling situation, and heparin plasma samples of four dogs in another sampling 423 situation. 424
During the sample collection of EDTA plasma and serum samples for the storage study, blood was drawn by cephalic 425 venipuncture into Vacuette serum gel tubes and Vacuette EDTA K2 tubes. Samples were centrifuged and separated 426 according to the tube manufacturers' recommendations. EDTA-plasma samples were immediately centrifuged and 427 plasma separated. Serum samples were allowed to clot for 30-45 minutes before centrifuging to separate serum. 428 Separated plasma and serum were divided into 24 aliquots and stored in conditions outlined in Table 1 before 429 immediate analysis with proton NMR spectroscopy. 430 Lithium Heparin tubes. Samples were immediately centrifuged and plasma separated. The samples were divided into 13 432 aliquots and stored in conditions outlined in Table 4 . After storage of samples in these test conditions, all samples were 433 kept at -80°C for 2-3 weeks before NMR analysis. 434 (Table 4) oof the sample i exceeded or undercut these cut points, it was defined as an outlier. All 465 analyses were done as outliers included or not excluded in purpose to study the effect of outlier exclusion. 466
The criteria for clinically significant change was set so, that the change should be both statistically significant (p-value 467 of the two-sided Wilcoxon exact test <0.05) and the magnitude of the change, evaluated as MPD, was required to be 468 above the ACL, and the change was required to be consistent at the remaining time points. Sample stability was studied 469 only in primary analytes, analyte stability was not evaluated in ratio and percentage analytes. 470
Delayed plasma separation study 471 manufacturer's recommendations affect metabolite values. Delayed plasma separation was studied by storing samples 473 as whole blood in refrigerated temperature for 24 and 48 hours before plasma separation. 474
Blood was drawn by cephalic venipuncture from 34 client-owned dogs into three Vacuette K2 EDTA tubes per dog. 475
One of the tubes was centrifuged and plasma separated according to sample tube manufacturer's recommendations 476 within one hour after blood sampling. The remaining two tubes were stored as whole blood in a refrigerator until 477 centrifugation and plasma separation after 24 and 48 hours of storage. After plasma separation, all samples were stored 478 at -80°C before NMR analysis. This experiment was conducted using an older version of the NMR testing platform, 479 thus the number of tested analytes was smaller, and fatty acids were not quantified. 480
For statistical analyses, we used similar methods as in the sample storage study. We used the two-sided Wilcoxon exact 481 test to assess the effect of storage time on the sample, and mean percentage deviation (MPD) to indicate 482 stability/instability and magnitude of change. Acceptable change limits (ACL) were the same as in the storage study. 483
Outlier detection followed the same procedure as in the storage study, and criteria for clinically significant change were 484 set similarly as p < 0.05 and MPD>ACL. T 0 in the delayed plasma study represents plasma separated according to 485 sample tube manufacturer's recommendations and T x plasma separated after 24 and 48 hours. 486
Sample tube validation 487
To study, whether metabolite values differ between samples collected in different blood collection tubes (BCT), we 488 studied both differences between different blood collection tubes and lot-to-lot variability within these tubes. The 489 protocol was modified from the proposed blood collection tube validation process by Bowen and Adcock 69 . 490 Thirty milliliters of blood was drawn from a cephalic iv-cannula from 20 dogs into seven different types of blood 491 collection tubes; MiniCollect Serum Separator Clot Activator tube, Vacuette Z Serum Separator Clot Activator tube, 492
Vacuette Z Serum Clot Activator tube, Vacuette K2 EDTA tube, MiniCollect Lithium Heparin Separator tube, Vacuette 493 Lithium Heparin tube and Vacuette Lithium Heparin Separator tube. Each tube type was tested with two tubes from 494 different lots. EDTA and lithium heparin samples were immediately centrifuged to separate plasma. Serum samples 495 were allowed to clot for 30-45 minutes before serum separation. The centrifugation conditions for samples collected 496 into MiniCollect tubes were 3,000 x g for 10 minutes, and 2,000 x g for 13 minutes for all other sample tube types. The 497 tested sample tubes and their specifications are presented in Table 5 . All samples were stored at -80°C before analysis 498 with NMR spectroscopy. The sample tube validation was only conducted regarding primary analytes, not for ratio and 499 percentage analytes. 500 Differences between different sample tubes were tested using this protocol: 506 1) Study, which tubes give comparable results with the primary reference tube 507
The Vacuette Lithium Heparin tube was set as the primary reference tube (T 0 ) and all other tubes (T x ) were compared 508 against it. 509
Since we hypothesized, that most of the differences between sample tubes would originate from differences between 510 serum and plasma, we secondly studied, which serum tubes give comparable results. 511 2) Study, which serum tubes give comparable results with the serum reference tube. 512
The Vacuette Z Serum Clot Activator tube was set as the serum reference tube (T 0 ) and all other serum tubes (T x ) were 513 compared against it. 514
515
The average of the analyte values in the two lots was used in these calculations. 516
Lot-to-lot variability was tested using this protocol: 518 1) Compare the two lots of each tube to another. 519 Tubes in lot A were set as a reference tubes (T 0 ) and tubes in lot B (T x ) were compared against them 520
2) If lot-to-lot variability was observed, compare results of each lot to reference tubes. This was done to determine, 521 whether samples from both lots give comparable results to the other tube types. 522
Lots A and B were compared separately to the Vacuette Lithium Heparin and Vacuette Z Serum Clot Activator tubes. 523
524
The same outlier detection protocol was used as in the sample storage study (2.4), except that we used coefficient 3 for 525 STD (instead of 2) in cut points:
We set broader cut off limits for outlier detection for the 526 sample tube validation than for the storage study, since the outlier test was more sensitive due to more observations in 527 the sample tube validation than in the storage study. 528
In addition to the tests above, we calculated bias as mean difference of T x and T 0 with 95% confidence intervals, to 529 highlight the limits in which the differences of the samples in tubes (or lots) T x and T 0 lie. 530
Although metabolite quantification is possible from citrate tubes, we did not include this tube type in this study, since 531 this tube type is not generally used in clinical applications in this field. 532
Interference 533
We tested our metabolites for interference of hemolysis, lipemia, and unconjugated and conjugated bilirubin. The 534 testing protocol was derived from CLSI-EP7-A2 70 . 535
Hemolysis interference was studied using two client-owned dogs. 5 ml heparinized blood was collected by cephalic 536 venipuncture for preparation of the hemolysis stock solution. The samples were centrifuged and plasma separated and 537 discarded. The red blood cells were saved for the preparation of hemolysis stock solution. The hemolysis stock solution 538 was prepared by the osmotic shock procedure. The hemoglobin concentrations of the hemolysates were measured by 539 ADVIA 2120i hematology analyzer (Siemens) 71 . The base of the test and control samples were created by collecting 540 5ml heparinized blood by cephalic venipuncture from the same dogs that were used for the preparation of the 541 hemoglobin stock solutions. Test samples containing 500 mg/dl hemoglobin were produced by adding a measured 542 volume of the same dog's hemolysate to the same dog's plasma sample to produce the end concentration of 500mg/dl 543 hemoglobin. Test samples containing 250mg/dl hemoglobin were prepared by mixing an equal amount of the same 544 dog's hemoglobin 500mg/dl test and control samples. All samples were divided into three aliquots and run as triplicates 545 in the NMR analysis. 546
Bilirubin interference was studied by creating two sample pools (Pool 1 and Pool 2) from samples collected for the 547 canine NMR metabolomics project. The sample pools were created so, that as many metabolite levels as possible would 548 differ between the two pools. The baseline bilirubin concentrations of both pools were measured (540 nm) by a 549 modified version of the acid diazo coupling (Malloy-Evelyn) method (Bilirubin Total (NBD), Thermo Fisher Scientific 550 Oy, Finland), using a Konelab 60i chemistry analyzer 72 . The two pools were both divided into four pools, creating the 551 bases for test and control pools for unconjugated bilirubin, and test and control pools for conjugated bilirubin. The test 552 pools for conjugated bilirubin were prepared by adding bilirubin stock solution (201102 EMD Millipore) to the 553 conjugated bilirubin test pool samples. The control pools for conjugated bilirubin were prepared by adding the same 554 volume of water to the conjugated bilirubin control pool samples. The test pools for unconjugated bilirubin were 555 prepared by adding bilirubin stock solution (2011 EMD Millipore) to the unconjugated bilirubin test pools. The control 556 pools for unconjugated bilirubin were prepared by adding the same volume of NaOH to the unconjugated bilirubin 557 control pool samples. All pools were divided into three aliquots and run as triplicates in the NMR analysis. 558
Lipemia interference was studied by pooling lipemic serum samples collected for the canine NMR metabolomics 559 project. The test pool was created so, that the triglyceride concentration would be around 2mmol/l. The pool was 560 divided into a test and control pool. The lipids of the control pool were cleared by ultracentrifugation. Both samples 561 were divided into three aliquots and run as triplicates by NMR. 562
We used CLSI-EP7-A2 70 guidelines as the base for our statistical testing. Interference testing was only evaluated 563 regarding primary analytes, analyte stability was not evaluated in ratio and percentage analytes. Our testing was based 564 , where d null represented the assumed difference between the 571 means of test and control samples (set to 0), n was the number of replicates (n=3) and s was the mean within-laboratory 572 standard deviation (S T ) of non-lipemic samples obtained from the precision study results presented in this study. 95% 573 confidence intervals for the d ୭ ୠ ୱ were calculated as
. 575 We established our decision of interference in the lower 95% limit of interference limit interference was only evaluated for molecules other than lipids, since the lipid removal process inevitably decreases the 580 concentration of these molecules. 581
Method comparison 582
The method comparison study was designed to evaluate, whether results from the routine clinical chemistry analytes 583 included in the NMR metabolomics platform are comparable with results obtained by a conventional clinical chemistry 584 method. The evaluated analytes were glucose, lactate, creatinine, albumin, cholesterol and triglycerides. In this study, 585 bias was only evaluated as a measure of method interchangeability, since the values obtained by the conventional 586 method cannot be regarded as true values of the analyte. 587 588 Clinical canine samples (n = 999) were studied by both NMR and standard clinical chemistry analysis methods. The 589 samples included both heparin plasma and serum samples. The used samples were routine diagnostic sample material 590 submitted by veterinarians across Finland, sent by mail to a single laboratory provider (Movet Ltd, Kuopio, Finland). 591
Upon arrival, the samples were divided into two aliquots. One aliquot was immediately analyzed with conventional 592 laboratory methods. Triglycerides were analyzed by a photometric method, cholesterol by a colorimetric method, 593 albumin by a colorimetric method using bromcresol green, glucose by a photometric method using hexokinase, 594 creatinine by a colorimetric enzymatic method and lactate by an enzymatic photometric method. The other aliquot was 595 frozen and kept at -20°C for a maximum of 4 weeks before shipment to NMR analysis. The samples were sent in three 596 batches on cool packs to NMR analysis, shipping time 7-14 hours. After arrival at the NMR laboratory, the samples 597 were again stored at -80°C before NMR analysis. One of the sample shipments was sent over a 14h period on cool 598 packs and partly thawed during shipment. Samples that were sent with a 7h shipment duration remained frozen during 599 transportation. 404 of the samples were used for scaling the NMR albumin measurement, and thus excluded from the 600 method comparison of albumin. using a comparison plot with values the NMR method plotted on the y-axis and the conventional method on the x-axis. 603 Agreement plots were created for raw data and logarithm transformed data. Bland-Altman plots 74 were used to 604 visualize the distribution of differences. 605
606
We utilized Deming regression 75,76 in calculation of slope and intercept for all analytes, and in addition, linear 607 regression for analytes with correlation over 0,99. Agreement of Deming transformed data was visualized by adding an 608 agreement plot for data in which conventional method data was transformed using Deming regression coefficients. To 609 determine the mean bias in the unit of the analyte at both ends of the reference intervals, bias was determined by slope 610 x 1 0 0 .
622

Hyperglycemia-associated biomarkers 623
In order to demonstrate the utility of the developed method in an important biological question, we studied the 624 differences in metabolite profiles in a hyperglycemic and normoglycemic group. We used the results of the 999 clinical 625 canine samples utilized in the method comparison study as our base population for the study. No clinical data was 626 available for the samples. 627
